Intra-Cellular Therapies, Inc.ITCI was a big mover last session with its shares rising roughly Array0% on the day. The upside owed to the company's announcement of financial results for the fourth quarter and full year ended Dec 3Array, 20Array5, and corporate updates on its ongoing development programs. This development led to far more shares changing hands on Friday than in a normal session. The move reverses the recent downtrend of the company as the stock has lost over 2% in the last five trading sessions.
This biopharmaceutical company focused on the development of therapeutics for central nervous system disorders has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Friday's rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Intra-Cellular Therapies currently has a Zacks Rank #3 (Hold).
Investors interested in the med-biomed/gene space may however consider Actelion Ltd. ALIOF which sports a Zacks Rank #Array (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>